Vitamin D receptor knockdown attenuates the antiproliferative, pro‑apoptotic and anti‑invasive effect of vitamin D by activating the Wnt/β‑catenin signaling pathway in papillary thyroid cancer

Pang,Rui; Xu,Ye; Hu,Xiaonan; Liu,Bo; Yu,Jiawei

doi:10.3892/mmr.2020.11522

Vitamin D receptor knockdown attenuates the antiproliferative, pro‑apoptotic and anti‑invasive effect of vitamin D by activating the Wnt/β‑catenin signaling pathway in papillary thyroid cancer

Authors:
- Rui Pang
- Ye Xu
- Xiaonan Hu
- Bo Liu
- Jiawei Yu
View Affiliations

Affiliations: Department of Head and Neck Thyroid, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang 150040, P.R. China, Department of Gynecology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang 150040, P.R. China, Department of Head and Neck Radiotherapy, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang 150040, P.R. China
Published online on: September 17, 2020 https://doi.org/10.3892/mmr.2020.11522
Pages: 4135-4142
Copyright: © Pang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Vitamin D and the vitamin D receptor (VDR) complex have been reported to inhibit the growth of several types of tumor; however, their function in papillary thyroid cancer (PCT) remains unknown. In addition, the Wnt/β‑catenin signaling pathway was discovered to serve a critical role in the pathology of PCT. Therefore, the present study aimed to determine the role of the VDR and its association with Wnt/β‑catenin signaling in vitamin D‑treated PTC cells. VDR expression was detected in human PTC cells (including MDA‑T120, MDA‑T85, SNU‑790 and IHH4 cells) and thyroid follicular cells (Nthy‑ori 3‑1 cells). SNU‑790 and IHH4 cells were infected with KD‑VDR or negative control (KD‑NC) lentiviruses, treated with 1,25(OH)2D3 (the active form of vitamin D), and subsequently referred to as the KD‑VDR&vitD and KD‑NC&vitD groups, respectively. Additionally, PTC cells infected with KD‑NC and not treated with 1,25(OH)2D3 were used as the normal control and referred to as the KD‑NC group. VDR mRNA and protein expression levels were increased in MDA‑T120, SNU‑790 and MDA‑T85 cells compared to Nthy‑ori 3‑1 cells, whereas in IHH4 cells, VDR mRNA and protein expression levels were similar to Nthy‑ori 3‑1 cells. In SNU‑790 and IHH4 cells, cell proliferation and invasion were decreased in the KD‑NC&vitD group compared with the KD‑NC group, but increased in the KD‑VDR&vitD group compared with the KD‑NC&vitD group. Cell apoptosis was increased in the KD‑NC&vitD group compared with the KD‑NC group, and decreased in the KD‑VDR&vitD group compared with the KD‑NC&vitD group. Furthermore, the expression levels of Wnt family member 3 and catenin β1 were decreased in the KD‑NC&vitD group compared with the KD‑NC group, but increased in the KD‑VDR&vitD group compared with the KD‑NC&vitD group. In conclusion, the present study revealed that VDR‑KD attenuated the antiproliferative, pro‑apoptotic and anti‑invasive effects of vitamin D in PTC by activating the Wnt/β‑catenin signaling pathway.

View Figures

View References

1	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
2	Wang J, Yu F, Shang Y, Ping Z and Liu L: Thyroid cancer: Incidence and mortality trends in China, 2005–2015. Endocrine. 68:163–173. 2020. View Article : Google Scholar : PubMed/NCBI
3	Haddad RI, Nasr C, Bischoff L, Busaidy NL, Byrd D, Callender G, Dickson P, Duh QY, Ehya H, Goldner W, et al: NCCN Guidelines insights: Thyroid carcinoma, version 2.2018. J Natl Compr Canc Netw. 16:1429–1440. 2018. View Article : Google Scholar : PubMed/NCBI
4	Kim HI, Jang HW, Ahn HS, Ahn S, Park SY, Oh YL, Hahn SY, Shin JH, Kim JH, Kim JS, et al: High serum TSH level is associated with progression of papillary thyroid microcarcinoma during active surveillance. J Clin Endocrinol Metab. 103:446–451. 2018. View Article : Google Scholar : PubMed/NCBI
5	Amouri W, Charfeddine S, Charfi S, Jardak I, Boudawara T and Guermazi F: Clinicopathological features and outcomes after radioactive iodine treatment of oncocytic well-differentiated thyroid carcinomas. Nucl Med Commun. 40:888–893. 2019. View Article : Google Scholar : PubMed/NCBI
6	Price AK, Randle RW, Schneider DF, Sippel RS and Pitt SC: Papillary thyroid microcarcinoma: Decision-making, extent of surgery, and outcomes. J Surg Res. 218:237–245. 2017. View Article : Google Scholar : PubMed/NCBI
7	Lee YC, Na SY, Park GC, Han JH, Kim SW and Eun YG: Occult lymph node metastasis and risk of regional recurrence in papillary thyroid cancer after bilateral prophylactic central neck dissection: A multi-institutional study. Surgery. 161:465–471. 2017. View Article : Google Scholar : PubMed/NCBI
8	Uitterlinden AG, Fang Y, Van Meurs JB, Pols HA and Van Leeuwen JP: Genetics and biology of vitamin D receptor polymorphisms. Gene. 338:143–156. 2004. View Article : Google Scholar : PubMed/NCBI
9	Bizzaro G, Antico A, Fortunato A and Bizzaro N: Vitamin D and autoimmune diseases: Is Vitamin D receptor (VDR) polymorphism the culprit? Isr Med Assoc J. 19:438–443. 2017.PubMed/NCBI
10	Hewison M: Vitamin D and the intracrinology of innate immunity. Mol Cell Endocrinol. 321:103–111. 2010. View Article : Google Scholar : PubMed/NCBI
11	Huss L, Butt ST, Borgquist S, Elebro K, Sandsveden M, Rosendahl A and Manjer J: Vitamin D receptor expression in invasive breast tumors and breast cancer survival. Breast Cancer Res. 21:842019. View Article : Google Scholar : PubMed/NCBI
12	Li M, Liu X, Liu N, Yang T, Shi P, He R and Chen M: Association between polymorphisms of Vitamin D receptor and lung cancer susceptibility: Evidence from an updated Meta-analysis. J Cancer. 10:3639–3649. 2019. View Article : Google Scholar : PubMed/NCBI
13	Joanna B, Jolanta B, Agnieszka G, Diana HZ and Krystyna S: Vitamin D, linoleic acid, arachidonic acid and COX-2 in colorectal cancer patients in relation to disease stage, tumour localisation and disease progression. Arab J Gastroenterol. 20:121–126. 2019. View Article : Google Scholar : PubMed/NCBI
14	Trump DL and Aragon-Ching JB: Vitamin D in prostate cancer. Asian J Androl. 20:244–252. 2018. View Article : Google Scholar : PubMed/NCBI
15	Feldman D, Krishnan AV, Swami S, Giovannucci E and Feldman BJ: The role of vitamin D in reducing cancer risk and progression. Nat Rev Cancer. 14:342–357. 2014. View Article : Google Scholar : PubMed/NCBI
16	Skrajnowska D and Bobrowska-Korczak B: Potential Molecular Mechanisms of the Anti-cancer Activity of Vitamin D. Anticancer Res. 39:3353–3363. 2019. View Article : Google Scholar : PubMed/NCBI
17	Al-Hendy A, Diamond MP, Boyer TG and Halder SK: Vitamin D3 inhibits Wnt/β-catenin and mTOR signaling pathways in human uterine fibroid cells. J Clin Endocrinol Metab. 101:1542–1551. 2016. View Article : Google Scholar : PubMed/NCBI
18	Samuel S and Sitrin MD: Vitamin Ds role in cell proliferation and differentiation. Nutr Rev. 66 (Suppl 2):S116–S124. 2008. View Article : Google Scholar : PubMed/NCBI
19	Zhang T, Zhang H, He L, Wang Z, Dong W, Sun W and Zhang P: Potential use of 1–25-dihydroxyvitamin D in the diagnosis and treatment of papillary thyroid cancer. Med Sci Monit. 24:1614–1623. 2018. View Article : Google Scholar : PubMed/NCBI
20	Izkhakov E, Somjen D, Sharon O, Knoll E, Aizic A, Fliss DM, Limor R and Stern N: Vitamin D receptor expression is linked to potential markers of human thyroid papillary carcinoma. J Steroid Biochem Mol Biol. 159:26–30. 2016. View Article : Google Scholar : PubMed/NCBI
21	Zhang J, Gill AJ, Issacs JD, Atmore B, Johns A, Delbridge LW, Lai R and McMullen TP: The Wnt/β-catenin pathway drives increased cyclin D1 levels in lymph node metastasis in papillary thyroid cancer. Hum Pathol. 43:1044–1050. 2012. View Article : Google Scholar : PubMed/NCBI
22	Wang Y, Huang H, Hu F, Li J, Zhang L and Pang H: CITED1 contributes to the progression of papillary thyroid carcinoma via the Wnt/β-catenin signaling pathway. Onco Targets Ther. 12:6769–6777. 2019. View Article : Google Scholar : PubMed/NCBI
23	Tomas G, Tarabichi M, Gacquer D, Hebrant A, Dom G, Dumont JE, Keutgen X, Fahey TJ III, Maenhaut C and Detours V: A general method to derive robust organ-specific gene expression-based differentiation indices: Application to thyroid cancer diagnostic. Oncogene. 31:4490–4498. 2012. View Article : Google Scholar : PubMed/NCBI
24	Giordano TJ, Kuick R, Thomas DG, Misek DE, Vinco M, Sanders D, Zhu Z, Ciampi R, Roh M, Shedden K, et al: Molecular classification of papillary thyroid carcinoma: Distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis. Oncogene. 24:6646–6656. 2005. View Article : Google Scholar : PubMed/NCBI
25	He H, Jazdzewski K, Li W, Liyanarachchi S, Nagy R, Volinia S, Calin GA, Liu CG, Franssila K, Suster S, et al: The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci USA. 102:19075–19080. 2005. View Article : Google Scholar : PubMed/NCBI
26	Zhu X, Yao J and Tian W: Microarray technology to investigate genes associated with papillary thyroid carcinoma. Mol Med Rep. 11:3729–3733. 2015. View Article : Google Scholar : PubMed/NCBI
27	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
28	Tagliabue E, Raimondi S and Gandini S: Vitamin D, cancer risk, and mortality. Adv Food Nutr Res. 75:1–52. 2015. View Article : Google Scholar : PubMed/NCBI
29	Robsahm TE, Tretli S, Torjesen PA, Babigumira R and Schwartz GG: Serum 25-hydroxyvitamin D levels predict cancer survival: A prospective cohort with measurements prior to and at the time of cancer diagnosis. Clin Epidemiol. 11:695–705. 2019. View Article : Google Scholar : PubMed/NCBI
30	Rohan JN and Weigel NL: 1Alpha,25-dihydroxyvitamin D3 reduces c-Myc expression, inhibiting proliferation and causing G1 accumulation in C4-2 prostate cancer cells. Endocrinology. 150:2046–2054. 2009. View Article : Google Scholar : PubMed/NCBI
31	Choi JY, Yi JW, Lee JH, Song RY, Yu H, Kwon H, Chai YJ, Kim SJ and Lee KE: VDR mRNA overexpression is associated with worse prognostic factors in papillary thyroid carcinoma. Endocr Connect. 6:172–178. 2017. View Article : Google Scholar : PubMed/NCBI
32	Liu KH, Fu J, Zhou N, Yin W, Yang YY, Ouyang SX and Liang YM: 1,25-Dihydroxyvitamin D3 prevents epithelial-mesenchymal transition of HMrSV5 human peritoneal mesothelial cells by inhibiting histone deacetylase 3 (HDAC3) and increasing Vitamin D receptor (VDR) expression through the Wnt/β-catenin signaling pathway. Med Sci Monit. 25:5892–5902. 2019. View Article : Google Scholar : PubMed/NCBI
33	Horas K, Zheng Y, Fong-Yee C, Macfarlane E, Manibo J, Chen Y, Qiao J, Gao M, Haydar N, McDonald MM, et al: Loss of the vitamin d receptor in human breast cancer cells promotes epithelial to mesenchymal cell transition and skeletal colonization. J Bone Miner Res. 34:1721–1732. 2019. View Article : Google Scholar : PubMed/NCBI
34	Kim D: The role of Vitamin D in thyroid diseases. Int J Mol Sci. 18:19492017. View Article : Google Scholar
35	Zheng Y, Trivedi T, Lin RC, Fong-Yee C, Nolte R, Manibo J, Chen Y, Hossain M, Horas K, Dunstan C, et al: Loss of the vitamin D receptor in human breast and prostate cancers strongly induces cell apoptosis through downregulation of Wnt/β-catenin signaling. Bone Res. 5:170232017. View Article : Google Scholar : PubMed/NCBI
36	Zhang X, Li M, Zuo K, Li D, Ye M, Ding L, Cai H, Fu D, Fan Y and Lv Z: Upregulated miR-155 in papillary thyroid carcinoma promotes tumor growth by targeting APC and activating Wnt/β-catenin signaling. J Clin Endocrinol Metab. 98:E1305–E1313. 2013. View Article : Google Scholar : PubMed/NCBI
37	Welsh J: Vitamin D and breast cancer: Past and present. J Steroid Biochem Mol Biol. 177:15–20. 2018. View Article : Google Scholar : PubMed/NCBI